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Aims With the success of antiretroviral therapy (ART), non-human immunodeficiency virus (HIV)-related comorbidities like
cardiovascular diseases (CVDs) are of increasing concern.We describe important recent research developments on the
epidemiologyofCVD inHIV infection, ART-relatedmetabolic changes, and cardioprotective anti-inflammatorymechan-
isms, and summarize management strategies for CVD risk reduction.
Methods
and results
We systematically identified and analysed systematic reviews and most cited literature published in the last 3 years and
supplemented findings with selected evidence based on clinical expertise. Among HIV-infected individuals, the preva-
lence of CVD risk factors and the risk for CVD is higher compared with HIV negatives. Antiretroviral drugs may
induce dyslipidaemia, reduce insulin sensitivity, and promote body fat redistribution that additionally contributes to
CVD risk. Some antiretroviral drugs may increase risk for CVD events, but the absolute risk increase is moderate and
has to be put into perspectivewith themassiveHIV-related benefits. SustainedHIV suppression reduces systemic inflam-
matory markers and is associated with a moderate reduction in CVD events. Regular CVD risk assessment and counsel-
ling to stop smoking must be regularly done in all HIV-infected individuals. Statins are effective for the treatment of
dyslipidaemia in HIV infection, but drug interactions with ART need to be considered.
Conclusion Human immunodeficiency virus-infected individuals are at increased risk for CVD. Timely initiation of ART with conse-
quent viral suppression is likely to reduce CVD events and to offset potential side effects from ART-induced metabolic
changes. Reduction in smoking in HIV-infected individuals is a public health priority.
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Introduction
Antiretroviral therapy (ART) has led to a dramatic reduction in
acquired immunodeficiency syndrome (AIDS)-related morbidity
and mortality and human immunodeficiency virus (HIV) infection
has become a chronic condition. With the introduction of more
potent drugs, co-formulations and once daily to take drug regimens,
patients with excellent adherence and immunological response may
expect a life expectancy similar to non-HIV-infected individuals.1 In
parallel, a concomitant increase in morbidity and death not directly
related to HIV was noted. Among the many comorbidity conditions,
cardiovascular diseases (CVDs) have become of particular concern
due to antiviral-drug-inducedmetabolic changes, the high prevalence
of cardiovascular risk factors inHIV-infected individuals, and growing
evidence on HIV-accelerated inflammatory processes that are
known to promote atherosclerosis.
We give an umbrella review of up-to-date systematic reviews and
other important publications on the complex association of HIV in-
fection and CVD-related factors. We describe important recent
developments and perspectives based on a systematic analysis of
the most cited research in this field published in the last 3 years.
Details on our approach are given in Supplementary material online.
Cardiovascular disease risk in human
immunodeficiency virus-infected
compared to human immunodeficiency
virus-uninfected individuals
A meta-analysis found in HIV-infected untreated and treated indivi-
duals a significantly higher risk for CVD when compared with
HIV-uninfected individuals (1.61; 95% CI 1.43–1.83 and RR 2.00;
95% CI 1.70–2.37).2 Several studies included into this meta-analysis
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lacked data on traditional cardiovascular risk factors3 and findings of
increased CVD risk in HIV-infected individuals might partially be
explained by residual confounding.4However, studieswith appropri-
ate adjustment for these risk factors still show a substantially
increased CVD risk.5–7
Cardiovascular risk factors in human
immunodeficiency virus-infected
individuals
Substantial differences in cardiovascular risk profiles in HIV-infected
compared with uninfected individuals were noted in a routinely col-
lected data analysis from two large US hospitals between 1996 and
2004: among HIV-infected patients, a higher prevalence was found
for smoking (38 vs. 18%), hypertension (21 vs. 16%), diabetes (12
vs. 7%), and dyslipidaemia (23 vs. 18%).5 Similar rates were found in
analyses from Kaiser Permanente in Northern California, however,
rates of hypertension and diabetes were lower.6
The D:A:D study (Data Collection of Adverse events of Anti-HIV
Drugs) is one of the largest databases on cardiovascular risk factors
with 33 308 HIV-infected patients. During the 10-year observation
period (1999 to 2008), 289 of 2482 deaths in D:A:D were related
to CVD (rate ¼ 1.60 deaths/1000 person-years (PY)).8 The respect-
ive figureswere 743AIDS-relateddeaths (rate/1000 PY ¼ 4.12), 341
liver-related deaths (rate/1000 PY ¼ 1.89), and 286 non-AIDSmalig-
nancy deaths (rate/1000 PY ¼ 1.59). At baseline, almost 75% of indi-
viduals were in age groups where risk of CVD is generally low (,45
years in men, ,55 years in women), few had hypertension (8.5%),
very few were obese (BMI. 30 kg/m2; 3.5%) or had diabetes
(2.5%), or previous myocardial infarction (MI) and/or stroke
(1.4%). However, smoking rates were high (52%), 76% were male,
22% had a total cholesterol of ≥6.2 mmol/L, 34% had triglycerides
of ≥2.3 mmol/L, and 26% had a HDL-cholesterol of ≤0.9 mmol/
L.9 In D:A:D, a substantial discrepancy between ART-treated and
treatment-naı¨ve patients with regard to raised triglyceride and total
cholesterol levels was found, which was also observed in more
recent analyses.10 Although more HIV-infected patients are treated
with lipid and blood pressure-lowering drugs, data from a large
cohort study indicates that only modest decreases in lipid and
blood pressure values were noted over time.10,11
Dyslipidaemia
Following HIV infection, a decrease in total cholesterol, HDL-
cholesterol, and LDL-cholesterol but increase in triglycerides has
been observed in untreated individuals.12,13 After initiation of ART,
marked increases in total cholesterol, LDL-cholesterol, and triglycer-
ides are seenwithHDL-cholesterol remaining low.Theextentof lipid
changes differs between antiretroviral drugs and drug classes
(Table 1). First-generation compared with second-generation prote-
ase inhibitors (PIs; e.g. indinavir, lopinavir vs. atazanavir, and daruna-
vir) lead to higher increase in total cholesterol, LDL-cholesterol, and
triglycerides,15 whereas non-nucleoside reverse transcriptase inhibi-
tors (NNRTI; like efavirenz) lead to higher increase in total and
LDL-cholesterol compared with newer PIs.16 Typically, increases in
triglycerides are themost prominent lipid changes in ART recipients.
However, elevation of triglycerides carries only a spurious extra risk
for CHD in analyses adjusting for all remaining lipid parameters and
other CHD risk factors.17 Antiretroviral therapy-induced lipid
changes are in particular driven by a change in particle sizewith a pre-
ponderance of highly atherogenic small dense lipoproteins.18 Small
dense lipoproteins are increased in HIV-infected patients with a
CHD event and may be associated with a small additional risk for a
CHD event independent from other lipid parameters.19
In HIV-infected individuals, basal lipolysis and hepatic de novo
lipogenesis are increased, ability of insulin to suppress lipolysis in
adipocytes is reduced, and peripheral fatty acid trapping is
impaired.20 These mechanisms might be directly induced by HIV,
in particular due to circulating inflammatory cytokines like inter-
feron alfa.20
Lipodystrophy
Human immunodeficiency virus-infected patients may also experi-
ence important changes in body fat composition following exposure
to ART. Patients may develop lipoatrophy in the face and limbs or
lipohypertrophy with central visceral fat gain, increase in breasts or
ectopic fat deposition in liver, muscles, or adipose tissue and
develop, for example, a buffalo hump (Figure 1). Some patients may
experience both lipohypo- and hypertrophy. Nearly half of the
patients with long-term ART exposure develop changes in body
composition.21 The incidence in the Swiss HIV Cohort Study of any
self- or clinically reported body fat composition is 13.2 changes per
100 patient-years.22 An Italian study found incidence rates of lipoa-
trophy and fat accumulation of 8.2 and 4.8 per 100 PY, respectively.23
Simple anthropomorphic measures like waist circumference are
highly correlated with MRI-based anthropomorphic measure of fat
distribution and should therefore be used for routine monitoring in
ART recipients.24
Lipohypertrophy and visceral fat deposits in individuals receiving
ART is frequently associated with dyslipidaemia and hypertriglyceri-
demia, low-HDL-cholesterol, reduced insulin sensitivity, and dia-
betes.25 These metabolic changes resemble those found in
HIV-negative individuals with metabolic syndrome.26 Mechanisms
for lipohypertrophy are highly complex, different from those for
lipoatrophy, and not known in detail, but include elevation of inflam-
matory cytokines, high levels of circulating triglycerides, and free fatty
acids that are stored in the visceral fatty tissue and the liver.27,28
Increased levels of high-sensitivity C-reactive protein, adiponectin,
tumour necrosis factor-a, and Il-6 have been found in HIV-infected
men with lipohypertrophy similar to those seen in obese non-
HIV-infected men (Figure 2). Individuals with peripheral lipoatrophy
and central lipohypertrophy have increased Framingham risk
scores and higher coronary calcium scores and are thus at increased
risk for CHD.29,30 In a nested cohort study, lipoatrophy and lipohy-
pertrophy were both associated with increased overall mortality.31
Unfortunately, changes in body composition cannot be reverted to
a clinically relevant extent in most patients and are typically seen in
HIV-infected patients with long-time exposure, in particular, to first-
generation antiretroviral drugs.32,33
Insulin resistance and diabetes
The incidence of type II diabetes in theD:A:D study was 4.2 per 1000
PY.34 Low CD4 cell count (,200 cells/mL) and lipodystrophy
have been reported as HIV-related factors associated with type II
diabetes.34–36 In analyses of D:A:D and a recent analysis from
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Table 1 Summary of the associations of metabolic complications and cardiovascular disease with exposure to antiretroviral drugs from different classes (Adapted
from Table 13 in ‘Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents’14)
Adverse effects Nucleoside reverse transcriptase inhibitors Non-nucleoside reverse
transcriptase inhibitors
Protease inhibitors
Cardiovascular disease (CVD) Abacavir and didanosine: Associated with an increased risk
ofmyocardial infarction (MI) in some, but not all, cohort
studies. Absolute risk greatest in patients with
traditional CVD risk factors
Protease inhibitors: Associated with MI and stroke in some
cohort studies. Data on newer Pls (Atazanavir,
Darunavir, and Tipranavir) are limited.
Saquinavir + Ritonavir, Atazanavir + Ritonavir, and
Lopinavir + Ritonavir: PR interval prolongation. Risks
include structural heart disease, conduction system
abnormalities, cardiomyopathy, ischemicheart disease,
and co-administration with drugs that prolong PR
interval.
Saquinavir + Ritonavir: QT interval prolongation in patients
in a healthy volunteer study. Risks include underlying
heart conditions, pre-existing prolonged QT or
arrhythmia, or use with other QT-prolonging drugs.
ECG is recommended before SQV initiation and
should be considered during therapy.
Diabetes mellitus/insulin resistance Didanosine, Stavudine, Zidovudine Reported for some protease inhibitors (Indinavir,
Lopinavir + ritonavir), but not all protease inhibitors
Dyslipidemia Stavudine . Zidovudine. Abacavir:
 LDL
 Triglycerides
Efavirenz:
 Triglycerides
 LDL
 HDL
All Ritonavir -boosted protease inhibitors:
 LDL,  Triglycerides,  HDL
Lopinavir + Ritonavir ¼ Fosamprenavir + Ritonavir and
Lopinavir + Ritonavir. Darunavir + Ritonavir and
Atazanavir + Ritonavir:
 Triglycerides
Order is alphabetical where not otherwise indicated; empty spaces in the table may mean no reported cases for the particular side effect or no data are available for the specific ARV drug class; for additional information please see Appendix B in
‘Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents’14.
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Denmark, none of the newer antiretroviral drugs significantly con-
tributed to the increased risk of diabetes (in contrast to previous
observations with older drugs).35,37 It appears that antiretroviral
drug-induced risk of diabetes is associated with the use of PIs of the
first-generation and with thymidine-containing analogues reverse
transcriptase inhibitors that have known mitochondrial toxicity.37
In non-resource-limited settings, these drugs have now been
greatly replaced in HIV care. Mitochondrial toxicity may lead to
impaired insulin sensitivity, and in vitro models indicate that first-
generation PIs block glucose transporter GLUT4 and may also
affect glucose-sensingb-cells, both causing impaired glucose sensitiv-
ity.38,39Other factors thatmay be associatedwith an increased risk of
diabetes are high-sensitivity C-reactive protein and tumour necrosis
factors 1 and 2.40
Chronic inflammation
A growing body of data indicate that HIV-related inflammatory and
immunologic processes may contribute to additional risk for cardio-
vascular events in HIV-infected patients. Most convincing evidence
for such a mechanism comes from the unanticipated findings from
the SMART trial.41 In SMART, HIV-infected were assigned to
continuous use of ART (viral suppression group) or treatment inter-
ruption (drug conservation group) with deferral of therapy until a
CD4+ count decrease ,250 cells/mL. The trial rationale was to
limit ART-related toxicity and cardiovascular side effects. The trial
was stopped prematurely, because patients in the drug conservation
arm experienced a higher hazard for AIDS or death. Intriguingly,
patients in the drug conservation group comparedwith the viral sup-
pressiongroupalsoexperiencedmoreCVDevents (1.3 vs. 0.8 events
per 100 PY; HR 1.6; 95% CI 1.0–2.5).
Subsequent studies from SMART showed that ART interruption
was associated with significant increases in blood levels of
interleukin-6 (IL-6) and D-dimer. Interleukin-6 is a non-specific
inflammatory biomarker (like high-sensitivity C-reactive protein)
and D-dimer is a fibrin degradation product which primarily reflects
increased activity in the thrombotic process and may be elevated in
response to inflammatory stimuli and bacterial translocation.
Chronic inflammatory processes in endothelial cells that promote
atherosclerosis represent a very complex interplay of inflammatory
cells with lymphocyte and macrophage activation, damage to the
mucosal barrier, metabolic changes, and other factors directly or in-
directly related to HIV replication.
Higher levels of IL-6, high-sensitivity C-reactive protein, and
D-dimer were associated with increased all-cause mortality42 and
predicted CVD independent of other risk factors43 (Table 2).
However, the model improvement for risk prediction when added
to the Framingham risk score was modest. For each marker, the in-
crease in risk from the lowest to highest quartile, i.e. the risk differ-
ence between someone with blood levels ,75% of the population
comparedwith someonewith blood levels.75% of the population,
corresponds to twoadditional cardiovascularevents per100patient-
years.43 The association of high-sensitivity C-reactive protein, IL-6,
and D-dimer with all-cause mortality was also seen in nested case–
control studies, one including individuals with very advanced im-
munosuppression and high rate or previous AIDS.47 There is
further evidence that HIV-infected individuals with advanced im-
munosuppression (,200 CD4 cells/mL) and not fully suppressed
viral load (.500 copies/mL) have a higher prevalence of elevated
Il-6, D-dimer, and soluble CD14 than HIV-uninfected individuals of
similar CVD risk.45
Soluble CD14 is a marker for monocyte and macrophage activa-
tion and was in an additional nested case–control study of SMART
associated with increased odds for death but not CVD50 (Table 2).
Human immunodeficiency virus may lead to a compromised
mucosal barrier resulting in subsequent translocation of microbial
products, such as lipopolysaccharide that bind to soluble CD14
and may lead to systemic immune activation.
Figure1 A, B: Lipodystrophy in a HIV-infected patient (FromNewEngland Journal of Medicine, AndrewCarr, David A. Cooper, Lipodysthrophy
Associatedwith anHIV-Protease Inhibitor, 339, 18, 1, Copyright` (1998)MassachusettsMedical Society. Reprintedwith permission fromMassachu-
setts Medical Society)
L.G. Hemkens and H.C. Bucher1376
Soluble CD163 is expressed by macrophages in atherosclerotic
plaques, correlates well with arterial inflammation as measured
with fluorine-2-deoxy-D-glucose positron emission, and may be a
more promising marker for endothelial inflammation in HIV infec-
tion.53 In a study of ART-treated patients with well-suppressed
viral load, arterial inflammation in the aorta was higher than in HIV-
negative healthy controls and of similar magnitude as in HIV-negative
patients with established atherosclerosis.51 Findings from this study
are particularly intriguing because all HIV-infected patients had
been well treated for years and this may indicate that endothelial in-
flammation in HIV infection may persist independently from ART.
Endothelial cells that are altered by injury or inflammation express
chemokines and vascular cell adhesionmolecule-1 (VCAM-1) which
have a prominent role for attracting monocytes and promoting in-
flammatory cell entry. Soluble VCAM-1 is increased in HIV infec-
tion49 and evidence from randomized controlled trials (RCTs)
indicates that ART reduces this endothelial activation marker.46,48
Similar core mechanisms of inflammation have been described in
the adipose tissue and adipocytes leading to the release of inflamma-
tory mediators or the migration of inflammatory cells into adipose
tissue and the exertion of systemic inflammatory responses.54
These similarities are of particular interest in HIV infection because
Figure 2 HIV and antiretroviral treatment (ART) might affect cardiovascular disease (CVD) through various pathophysiological pathways (to-
gether with environmental and genetic factors). There is a very complex interaction of various related factors. HIV and ART have direct effects
on adipose tissue and liver functionwith subsequent dyslipidemia, lipodystrophyand insulin resistance.Other direct impact includes effects on endo-
thelial cells and vascular smooth muscle cells leading to vascular and endothelial dysfunction with subsequent hypertension, atherosclerosis and
myocardial infarction. Continuous immune activation and viral replication might lead to a permanent T cell activation which might also be affected
bya reactivationofother viruses, e.g.Cytomegalovirus (CMV).ARTandHIVmight also stimulate achronic statusof inflammationandhave acomplex
interaction with coagulation factors. These pathways itself aremore or less interrelated andmediate indirect effects of HIV and ART onCVD. ART:
Antiretroviral therapy; hs-CRP: high-sensitivityC-reactiveprotein; F VII: FactorVII; FFA: Free fatty acids;HDLc:High-density lipoprotein cholesterol;
IL6: Interleukin 6; LPS: lipopolysaccharide; NO:Nitrogen oxide; PAI-1: Plasminogen activator inhibitor type 1; PPARy: peroxisome proliferator-acti-
vated receptors; RAS: Renin angiotensin system; ROS: Reactive oxygen species; sCD14: Soluble CD14; sCD163: Soluble CD163. Hypothetical
model for the pathogenesis of cardiovascular disease in HIV-infected persons taking antiretroviral therapy (based on a figure from Boccara et al.:
J Am Coll Cardiol, Franck Boccara, Sylvie Lang, Catherine Meuleman, Stephane Ederhy, Murielle Mary-Krause, Dominique Costagliola, Jacqueline
Capeau, Ariel Cohen, HIV and Coronary Heart Disease: Time for a Better Understanding, 61, 5, 511-523, Copyright (2013) Elsevier. Re-used
with permission from Elsevier)
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HIV and certain antiretroviral drugs can induce important metabolic
and body fat mass changes (Table 1). A model of the likely patho-
physiological mechanisms of atherosclerosis in HIV infection is pro-
vided in Figure 2.
Overall, there is a rapidly growing literature on inflammatory bio-
markers and CVD or surrogate markers of CVD (such as carotid
intimamedia thickness or coronary calcium score) inHIV infection.55
It needs to be emphasized that most of these studies use cross-
sectional or case–control designs and are explorative by nature.
The use of these biomarkers by clinicians as measures for comorbid-
ity for better risk prediction and/or targeted interventions will have
to be determined in clinical intervention trials, ultimately in RCTs.
Effects of antiretroviral drugs on
clinical cardiovascular disease
endpoints
A number of observational and experimental studies have examined
the effect of ART and risk for CVD. Two recently published system-
atic reviews collected, analysed, and synthesized the available litera-
ture.2,56 The more recent observational data meta-analysis by
Bavinger et al. showed an increased risk of MI associated with
recent exposure (e.g. within the last 6 months) to abacavir, a
reverse transcriptase inhibitor (RR 1.91; 95% CI 1.50–2.42) and PIs
(RR 2.13, 95% CI 1.05–1.17). Alternative analyses for cumulative
ART exposure suggest an increased risk for MI with each additional
year of treatment with the first-generation PIs indinavir (RR 1.11,
95% CI 1.05–1.17) and lopinavir (RR 1.22, 95% CI 1.01–1.47).
Studies included into thesemeta-analyseswereofmixedquality, esti-
mates between studies were heterogeneous and the summary find-
ings, therefore, have to be interpreted with caution. Following the
first publication of an increased risk of MI with abacavir exposure
by the D:A:D study investigators57 Cruciani et al. re-analysed in a
meta-analysis all RCTs comparing abacavirwith control reverse tran-
scriptase inhibitors thatwereprovidedby themanufacturerof abaca-
vir and a second analysis was conducted by the Federal Drug
Administration (FDA).58,59 It should be stressed that cardiovascular
events were only safety endpoints in all these trials and the statistical
power of these meta-analyses is limited. In both analyses, no
increased risk of MI with abacavir exposure was found with an RR
of 0.73 (95% CI 0.39–1.35), based on 18 RCTs and 7054 patients58
and an OR (Odds ratio) of 1.02 (95% CI 0.56–1.84), based on 26
trials and 9868 patients.59 Myocardial infarction was a rare event in
these analyses (3 events per 1000 patient-years of follow-up in
Cruciani et al., 46 events among 9868 patients in the FDA analysis)
and of similar frequency like in the D:A:D study.60 The D:A:D inves-
tigators also reported an increased CVD risk associated with the
older NRTI didanosine and Bavinger et al. also describe a harmful
association in a meta-analysis based on D:A:D and another, smaller,
observational study.56,57 Evidence from a few small studies indicates
that in HIV-infected individuals MI with ST elevation (STEMI) appear
to be slightly more frequent than non-STEMI MI.61
The excess risk for current use of didanosine and abacavir com-
pared with other reverse transcriptase inhibitors was in the range
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Table 2 Overview of reported effects of HIV infection and antiretroviral therapy on selected biomarkers and association
with clinical outcomes
Effect of HIV-infection Effect of ART Association with clinical
outcomes in HIV
Inflammation
IL-6 Blood levels increased (62–152%)44
Higher prevalence of elevated levels45
Decrease after initiation46
Increase after stopping38
All-cause mortality.38,47
CVD43
High-sensitivity C-reactive protein Blood levels increased (50–55%)44 Heterogeneous effects of
initiation or stopping 46,48
All-cause mortality.38,47
CVD43 (Not seen in19)
Thrombotic activity
D-Dimer Blood levels increased (94%)44
Higher prevalence of elevated levels45
Decrease after initiation48,49
Increased or no effect after
stopping 38,48
All-cause mortality38,47
CVD43 (Not seen in 19)
Monocyte and macrophage activation
sCD14 Blood levels increased
(unmatched data)50
Higher prevalence of elevated levels45
All-cause mortality47,50
sCD163 Increased blood levels51
Endothelial activation
sICAM-1/sVCAM-1 Increased blood levels49 Decrease after initiation46,48,49
Increase after stopping48
Highly atherogenic lipoproteins
VLDL No clear change of blood levels12,18 Elevated with ART18 CVD19 (Not seen in52)
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of 1 and 3 MIs per 1000 PY follow-up.57 Overall, based on the avail-
able evidence, it is unclear whether there is an increased risk for MI
associated with current abacavir use. A potentially existing absolute
risk increase with abacavir use would be moderate and needs to be
put into perspective with the massive benefit fromART and possible
side effects from other reverse transcriptase inhibitors.
Managing human
immunodeficiency virus and risk
factors for cardiovascular disease
Antiretroviral therapy
Growing evidence suggests that HIV suppression and improved
immune function is associated with reductions in systemic inflamma-
torymarkers and risk for aCVDevent. Thus, treatmentofHIVby sus-
tained and lifelong viral suppression has the first priority. For these
reasons, guidelines favour the initiation of antiretroviral treatment ir-
respective of CD4 cell counts in patients aged .50 years due to the
increased risk of serious non-AIDS events including CVD events.14
The benefit of early ART in patients not fulfilling the traditional
CD4-cell and viral-load-based criteria for ART initiation must be
balanced against the potential long-term side effects from ART,
which for many drugs are insufficiently known. The choice of the
regimen must therefore reflect the risk for CVD and other co-
morbidity, psychosocial conditions as well as patients’ preferences
and understanding to adhere to lifelong drug intake.
Cardiovascular disease risk prediction
Human immunodeficiency virus-infected patients are at increased
risk for CVD and therefore assessment of cardiovascular risk
should be routinely and regularly done in all patients and particular
in those receiving ART. A cardiovascular risk-assessment model
has been developed based on data from the D:A:D study with a
risk score calculator (http://www.cphiv.dk/TOOLS/Framingham/
tabid/302/Default.aspx) that besides established risk factors for
CVD includes exposure to antiretroviral drugswith known increased
risk of coronary heart disease (CHD) and/or CVD.62 Although the
validation of this tool had some limitations,63 this instrument has
been shown to predict the individual CVD risk marginally better
than the established Framingham risk functions.62 The Framingham
risk score tended to overpredict CHD in the general HIV population
but to underpredict CHD risk in the subgroups of females, former
smokers and diabetic patients. This tool seems to be currently the
best way to assess the individual cardiovascular risk in HIV-infected
patients but does not yet include inflammatory or immunologic
markers.
Modification of risk factors
Given the high prevalence of traditional risk factors for CVD in
HIV-infected individuals,managementof dyslipidaemia, hypertension
and counselling for behaviour changes is the first priority. Manage-
ment of such risk factors for CVD can, with few exceptions (see
below), be done according to guidelines established for non-HIV-
infected individuals.
Smoking
Because the prevalence of smoking in HIV-infected individuals is so
high, the reduction of smoking would lead to the highest absolute re-
duction in CVD. However, this goal is the most difficult to achieve.
Human immunodeficiency virus-infected individuals who succeed
in quitting experience marked reductions in CVD and CHD.64 Epi-
demiological data indicate that the number of patients receiving
blood pressure and lipid-lowering drugs has increased over time
but management of dyslipidaemia and hypertension in HIV infection
in particular among individuals at high risk remains insufficient.10,11
Dyslipidaemia
Treatment of dyslipidaemia inHIV-infected individuals receivingART
poses some particularities in relation to possible drug interactions
with antiretroviral drugs. There is no evidence fromRCTs investigat-
ing the efficacy of antilipidaemic (and antihypertensive) drugs for
patient-relevant endpoints inHIV-infected individuals and it is unlike-
ly that such trials will be ever conducted. Many RCTs comparing dif-
ferent antiretroviral drugs for antiretroviral efficacy, however, have
investigated the alteration of lipids in relation to different antiretro-
viral drug combinations. This trial data indicate that newer PIs (ataza-
navir and darunavir), NNRTIs (intelence), or integrase inhibitors
(raltegravir) induce less lipid changes. Substitution of antiretroviral
drug to less atherogenic drugs may be thus an option but can lead
to drug failure if previous drug failures, presence of drug resistance,
and issues of drug intake convenience are not carefully considered.
Therefore, the modification of a successful antiretroviral drug com-
bination should be made by the specialist.
Few RCTs have investigated statins in HIV-infected individuals
and found similar reductions of LDL-cholesterol compared with
HIV negatives.65–67 Fibrates, niacin, and fish-oil have all been
shown to effectively reduce ART-related increases in triglycerides
in HIV-infected patients.68,69 However, the use of these compounds
cannot be generally recommended given evidence based on patient-
important outcomes in HIV-negative individuals. Meta-analyses
of randomized trials with fibrates indicate a moderate reduction
in CHD events that is offset by an increase in non-CHD-related
mortality.70 Meta-analyses and clinical trials found no reduction in
CHD mortality when niacin was compared with placebo or added
to a statin.71,72 Large clinical trials of fish oil in patients at risk for
CHD indicate no benefit.73,74 Achievement of LDL-cholesterol
treatment goalswith dietary intervention and use of statins therefore
remains the first priority in the management of dyslipidaemia in
HIV-infected individuals at moderate to high risk for CHD.
Simvastatin, lovastatin, and atorvastatin are all metabolized in the
liver via the cytochromeP4503A4 isoenzymesystemand are suscep-
tible to drug interactionswith PIs and theNNRTI efavirenz.75 Fluvas-
tatin and, to a much smaller extent, rosuvastatin are primarily
metabolized via CYP 2C9 and are vulnerable to interactions with
PIs aswell. Pravastatin is not significantlymetabolized via theCYP iso-
enzyme system and is therefore a preferred statin in HIV-infected
individuals. The use of simvastatin and lovastatin in combination
with all PIs and efavirenz is not recommended (Table 3). Atorvastatin,
fluvastatin, and rosuvastatin when co-administered with PIs should
be initiated at the lowest dose and patients must be carefully moni-
tored because of the increased risk for potential drug interactions.
Drug interactions with antiretroviral drugs are best checked in the
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HIV–drug interaction database of the University of Liverpool (www
.hiv-druginteractions.org) and/or by checking interaction tables pro-
vided in treatment guidelines.14 The University of Liverpool inter-
action database offers excellent and easy-to-use online tools with
apps and downloadable interactions charts for lipid and blood
pressure-lowering drugs (Table 3).
Hypertension
Human immunodeficiency virus-infected patients with elevated
and not well-controlled blood pressure are at increased risk of a
CDV event.11 HIV-infected patients are also at increased risk for
developing end-stage renal failure. Reported risk factors for the de-
velopment of chronic kidney disease include ethnicity
(Afro-Americans), HIV-related factors (such as transmission
risk), concomitant diabetes and exposure to tenofovir, a nucleo-
tide reverse transcriptase inhibitors that is eliminated by the
kidney and very commonly used.76,77 Blood pressure management
recommendations for HIV-infected patients are similar to that for
HIV negatives but most importantly potential drug interactions
with antiretroviral drugs have to be kept in mind14,78,79: concomi-
tant use of diltiazem and atazanavir is problematic and all PIs may
increase levels of dihydropiridine calcium-channel-blockers (see
reference14 for details).
Alternative therapies
Sustained viral suppression reduces inflammatory markers and CVD
events. However, there is a growing evidence of continuing endothe-
lial inflammation activation in the presence of active ART.44 The
JUPITER trial has shown that rosuvastatin in patients with normal
LDL-cholesterol reduces high-sensitivity C-reactive protein and car-
diovascular events.80 Several ongoing trials are investigating whether
rosuvastatin or aspirin in HIV-infected patients with successfully
established ART may reduce systemic and endothelial inflammation
Table 3 Drug interactions between lipid-lowering and antiretroviral drugs (reproduced with kind permission of the
Liverpool HIV Pharmacology Group, University of Liverpool)
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markers, slow cIMT progression, or reduce prothrombotic
markers.81–83 Whether alternative anti-inflammatory drugs like
methotrexateorcanakinumabmaybe safely used andoffer additional
benefit in HIV-infected individuals with high-sensitivity C-reactive
protein and CVD risk needs to be carefully explored once results
from currently on-going large trials inHIV negatives are available.84,85
Conclusions
Human immunodeficiency virus-infected patients are at increased
risk for developing CVD due to the high prevalence of CVD risk
factors, ART-related metabolic changes, and systemic immune acti-
vation that promotes endothelial inflammation and atherosclerosis.
Timely initiating of ARTwith the goal of long-term sustained viro-
logical suppression of HIV for optimal immune reconstitution and
survival benefit is the first priority. Sustained virological response is
in addition associated with reduced levels of the inflammation
markers high-sensitivityC-reactive protein and IL-6 and amoderated
reduction in risk for CVD events. These benefits have to be balanced
against ART-induced metabolic changes.
The routine assessment of CVD risk based on the D:A:D risk
scores and consequent treatment of dyslipidaemia and hypertension
is paramount to reduce CVD risk in particular in individuals at mod-
erate to high risk and the second priority. Statins can effectively
improve ART-induced dyslipidaemia, but potential drug interactions
must be considered. Counselling for smoking cessation is of outmost
importance and referring motivated patients to stop smoking clinics
might have the highest impact on CVD risk reduction.
Antiretroviral drugsmay induce increases in cholesterol, triglycer-
ides, and LDL-cholesterol. Two first-generation PIs (indinavir and
lopinavir) seem to be associated with an increased CVD risk, the
data are less clear for the NRTI abacavir. However, such a risk in-
crease is moderate and has to be put into perspective with the
massive HIV-related benefits of these drugs. Therefore, the choice
of the optimal antiretroviral drug combinationmust be individualized
and reflect thepatient’s ability to adhere to therapy, andhisorher risk
for CVD and other comorbidity.
Optimally coordinated care between cardiovascular disease and
HIV specialists is paramount for the chronic disease management
of HIV and to further improve prognosis of patients living with HIV.
Supplementary material
Supplementary material is available at European Heart Journal online.
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